Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Complete title: A PHASE IB, OPEN-LABEL STUDY OF THESAFETY AND TOLERABILITY OF ATEZOLIZUMAB IN COMBINATION WITH RADIUM-223 DICHLORIDE IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING TREATMENT WITH AN ANDROGEN PATHWAY INHIBITOR

Research Study Number 20170291
 
Principal Investigator Tia Higano, MD
 
Phase I

Research Study Description

This study is designed to assess the safety and tolerability of atezolizumab when given in combination with radium-223 dichloride in participants with metastatic CRPC who have progressed after treatment with an androgen pathway inhibitor. An adaptive design is planned to first investigate the tolerability with concurrent administration (both treatments to begin in Cycle 1). However, if the combination is not tolerated, additional cohorts may be enrolled to evaluate the tolerability of radium-223 dichloride (to begin in Cycle 1) with delayed atezolizumab (to begin in Cycle 2 and/or 3).

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20170291
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Prostate Cancer; Solid Tumors; Prostate Cancer, Castration-resistant (CRPC); Urogenital Neoplasms; Genital Neoplasms, Male; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials